KIT and gastrointestinal stromal tumor: Since c-kit-overexpressing cancers, including gastrointestinal stromal tumors, could be treated with tyrosine kinase inhibitor, such as imatinib mesylate, it will be of interest to investigate whether malignant PTs may be responsive to c-kit inhibitors.